PBLSHealthcare · Biotechnology

PBLS Stock Forecast: Parabilis Medicines, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026

$38

−2.36% on the day

The 5 Wall Street analysts covering Parabilis Medicines, Inc. hold a median 12-month price target of $41 — +6.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$4.9B

Ticker Nerd rank

0 / 100

Median analyst target

$41

Analysts covering

Total return, dividends reinvested

+3.3%

+22.9%

From high

−7.0%

From low

+92.2%

$20

$41

Range since 8 June 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

PBLS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Parabilis Medicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

0 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions

Size

Value

Growth

Momentum

Accruals

Issuance

Quality

Volatility

Revisions (27): Analysts have, on balance, been raising their forecasts.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PBLS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PBLS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 8 June 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts

5 Buy0 Hold0 Sell

Low $40Median $41High $45

The green dot is the last close — the median target sits +6.7% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
6 July 2026	B of A Securities	Initiates	Buy	$45
6 July 2026	Guggenheim	Initiates	Buy	$40
6 July 2026	Leerink Partners	Initiates	Outperform	$40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PBLS appears on the weeks it earns a place.

Performance

PBLS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

PBLS vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PBLS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Parabilis Medicines, Inc. (PBLS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −21.8×
Price / sales: 32853.2×
Price / book: 4.6×
EV / EBITDA: −22.4×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: −34382.4%
Net margin: 0.0%

Returns & dividend

Return on equity: 1131.3%
Return on assets: −231.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Parabilis Medicines, Inc. (PBLS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Parabilis Medicines, Inc. has a market value of $4.9B and an enterprise value of $3.8B.
Shares outstanding: 118.1M.
Trailing P/E: −21.8×; forward P/E: −18.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Parabilis Medicines, Inc. employs 145 people.

market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

PBLS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
PBLSParabilis Medicines, Inc.	$4.9B	0
EWTXEdgewise Therapeutics, Inc.	$4.7B	51
CELCCelcuity, Inc.	$4.6B	30
DYNDyne Therapeutics, Inc.	$4.8B	29
ACADACADIA Pharmaceuticals, Inc.	$5.0B	82
ELVNEnliven Therapeutics, Inc.	$4.3B	68
MANEVeradermics, Inc.	$4.2B	2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Parabilis Medicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PBLS news & analysis

Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform

Seeking Alpha · 14 Aug 2026positive

The article discusses Parabilis Medicines' use of rare, genetically simple tumors to validate its Helicon platform for broader oncology applications. It notes the company holds $1.1 billion in cash with a runway into 2030, and reports early zolucatetide data in desmoid tumors showing 100% tumor reduction, 74% objective response, and a favorable safety profile versus competitors.

Why it matters — PBLS watchers would care because the early efficacy and safety data in desmoid tumors could serve as validation for the Helicon platform's applicability to broader oncology targets, supported by a long cash runway into 2030.

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · 13 Aug 2026positive

Parabilis Medicines reported its second quarter 2026 financial results and provided business updates. The company is advancing zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward a planned Phase 3 registrational trial in desmoid tumors.

Why it matters — A PBLS watcher would care because the update signals pipeline progress for zolucatetide, its lead candidate, moving toward a pivotal Phase 3 trial in desmoid tumors.

FAQ

Frequently asked questions about PBLS stock

What is the PBLS stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Parabilis Medicines, Inc. have a median 12-month price target of $41, with estimates ranging from $40 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PBLS stock a buy right now?

Of the 5 analysts covering Parabilis Medicines, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Parabilis Medicines, Inc. 0 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PBLS?

As at 22 Aug 2026, Parabilis Medicines, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (27 of 100).

Will PBLS stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +6.7% from the last close, and Ticker Nerd's factor model ranks Parabilis Medicines, Inc. 0 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PBLS stock forecast for 2030?

No analyst covering Parabilis Medicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBLS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $45 over the next 12 months.

What does Parabilis Medicines, Inc. do?

What is the latest news on PBLS?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform". The article discusses Parabilis Medicines' use of rare, genetically simple tumors to validate its Helicon platform for broader oncology applications. It notes the company holds $1.1 billion in cash with a runway into 2030, and reports early zolucatetide data in desmoid tumors showing 100% tumor reduction, 74% objective response, and a favorable safety profile versus competitors.

Company

About Parabilis Medicines, Inc.

Parabilis Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing ultra-tunable peptide therapeutics designed to modulate intracellular proteins that are traditionally difficult to target with conventional medicines. Its proprietary Helicon platform combines AI-driven design, high-throughput synthesis, and experimental screening to create stabilized helical peptides for precision drug development. The company’s current pipeline includes investigational programs for serious diseases such as cancer and other complex conditions, with lead efforts centered on zolucatetide, a direct inhibitor of the β-catenin:TCF interaction in the Wnt/β-catenin pathway. Parabilis Medicines also advances additional programs in targeted protein degradation and other intracellular mechanisms, reflecting its role in expanding the therapeutic reach of peptide-based medicines across oncology and related disease areas.

CEO Dr. Mathai Mammen M.D., Ph.D. · 145 employees · United States · https://parabilismed.com